Get started
Work

Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin

Year: 2021
Type: article
Abstract: The evidence for effectiveness of heterologous priming of COVID-19 vaccine is very limited. Here, we studied eighteen participants who received heterologous vaccination regimen of AstraZeneca’s ChAdOx1-nCov-19 followed by inactivated whole virion BBV152. Heterologous group participant doesn’t report any adverse event following immunization and demonstrated high humoral and neutralizing antibody response.
DOI: 10.1093/jtm/taab166
Authors: Rajni Kant, Gaurav Dwivedi, Kamran Zaman, Rima R Sahay, Gajanan Sapkal, Himanshu Kaushal, Dimpal A Nyayanit, Pragya D Yadav, Gururaj Deshpande, Rajeev Singh, Sandeep Chaowdhary, Nivedita Gupta, Sanjay Kumar, Priya Abraham, Samiran Panda, Balram Bhargava
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W3205697648
FWCI: 2.121
Cites: 25
Cited by: 27
Related to: 10